A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19)

Clin Infect Dis. 2021 Nov 2;73(9):e2845-e2846. doi: 10.1093/cid/ciaa1754.

Authors

Michael J Peluso¹, Sonia Bakkour², Michael P Busch², Steven G Deeks³, Timothy J Henrich⁴

Affiliations

¹ Division of Infectious Diseases, University of California, San Francisco, San Francisco, California, USA.
² Vitalant Research Institute, San Francisco, California, USA.
³ Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
⁴ Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Anti-HIV Agents* / therapeutic use
COVID-19*
HIV Infections* / drug therapy
HIV-1* / genetics
Humans
RNA / therapeutic use
SARS-CoV-2

Substances

Anti-HIV Agents
RNA

Grants and funding